NASA Awards Options for Two Joint Polar Satellite System Spacecraft
WASHINGTON, May 25, 2018 /PRNewswire-USNewswire/ -- NASA has exercised options under the Rapid Spacecraft Acquisition III (Rapid III) contract for two additional Joint Polar Satellite System (JPSS) spacecraft to be built for the National Oceanic and Atmospheric Administration (NOAA).
Orbital ATK of Dulles, Virginia, will build NOAA's Joint Polar Satellite System JPSS-3 and -4. The contract value is $460 million and the period of performance will extend through 2026. The work will be performed at Orbital ATK's facility in Gilbert, Arizona.
Orbital, which currently is developing the JPSS-2 spacecraft, will design, develop, fabricate, integrate, test and provide post-delivery support for the third and fourth spacecraft in the series.
JPSS satellites collect global, multi-spectral radiometry and other specialized meteorological, oceanographic data via remote sensing of land, sea and atmospheric properties. These data support NOAA's mission for continuous observation of Earth's environment to understand and predict changes in weather, climate, oceans and coasts.
NOAA funds the JPSS missions and NASA is the acquisition agent for the flight systems, launch services and components of the ground system.
Baxter International Inc. , a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on July 1, 2024, to stockholders of record as of May...
Cimpress plc today announced that Meredith Burns, Vice President of Investor Relations and Sustainability, will present at the Needham Technology, Media, & Consumer Conference on Wednesday, May 15, 2024, in New York, NY. Cimpress plc's presentation...
CLOC GLOBAL INSTITUTE-- Everlaw today announced new Legal Holds capabilities that control cost and risk by centralizing discovery and legal holds in one place, allowing legal teams to easily stay on top of legal holds and quickly discover insights...
Mirum Pharmaceuticals, Inc. today announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI® (maralixibat) oral solution in patients with PFIC was published in The Lancet Gastroenterology and Hepatology.
The MARCH-PFIC study was...
Mae Health Inc, announces the close of a seed raise, led by Jumpstart Nova, to scale its tech-enabled services offering to drive improvements in Black maternal health outcomes. Mae's round also included participation from new investors including the...
Gilead Sciences, Inc. and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform...
